HIVE Blockchain: Growth Amid Risks
HIVE Blockchain achieves neutral rating with price target of $3.50 as it increases production and sets ambitious hash rate targets, ...
- Latest
- Trending
HIVE Blockchain achieves neutral rating with price target of $3.50 as it increases production and sets ambitious hash rate targets, ...
A recent clinical trial in Japan reveals that virtual reality therapy can greatly improve the physical and emotional symptoms of ...
Kratos Defense secures a monumental $579 million contract for military satellite operations, bolstering its market position and commitment to US ...
Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...
KalVista Pharmaceuticals achieves key goals in late-stage study for hereditary angioedema therapy, demonstrating significant efficacy of sebetralstat. FDA approval filing ...
Regeneron Pharmaceuticals, a leading biopharmaceutical company, is gaining recognition for its innovative approach and strong financial performance. With a diverse ...
Otsuka's phase 3 trial for AVP-786 in treating agitation in Alzheimer's patients has failed to meet the primary efficacy endpoint. ...
BioVaxys Technology Corp. finalizes agreement to acquire IMV Inc.'s immunotherapy technology portfolio, expanding its cancer vaccine portfolio and positioning itself ...
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
FDA approves Takeda's EOHILIA as first-line treatment for Eosinophilic Esophagitis. Groundbreaking oral therapy offers hope for improved quality of life.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.